CANX and neoplasm: These results corroborate our theory that downregulation of PDIA3, HSPA5, and calnexin, at a certain point of tumor progression, may contribute to malignancy by promoting tumor-immune system evasion through a dysregulation in peptide processing and antigen presentation, having a direct impact on patient outcome and therapy efficiency.